Incretin‐based medications for type 2 diabetes: an overview of reviews

Publisher： John Wiley & Sons Inc

E-ISSN： 1463-1326|17|7|649-658

ISSN： 1462-8902

Source： DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol.17, Iss.7, 2015-07, pp. : 649-658

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Incretin-based therapies and their future in Type 2 diabetes mellitus

By Sonnett Travis E   Robinson Jennifer D   Bowen Kurt A  

Therapy, Vol. 8, Iss. 2, 2011-03 ,pp. : 143-152

Future Medicine

Access to resources Recommend Favorite

Incorporating Incretin-Based Therapies into Clinical Practice for Patients with Type 2 Diabetes

By Tibaldi Joseph  

Advances in Therapy, Vol. 31, Iss. 3, 2014-03 ,pp. : 289-317

Springer Publishing Company

Access to resources Recommend Favorite

Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies

By Meece Jerry  

Current Medical Research and Opinion, Vol. 23, Iss. 4, 2007-04 ,pp. : 933-944

Informa Healthcare

Access to resources Recommend Favorite

Sodium‐glucose cotransporter‐2 inhibition improves incretin sensitivity of pancreatic β‐cells in people with type 2 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 370-377

John Wiley & Sons Inc

Access to resources Recommend Favorite

Implications of incretin‐based therapies on cardiovascular disease

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 5, 2015-05 ,pp. : 531-549

John Wiley & Sons Inc

Access to resources Recommend Favorite